Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
The purpose of this phase II clinical trial was to evaluate the effectiveness of triazinate and pyrazofurin in the treatment of advanced breast cancer. Although an occasional patient experienced stability of disease, neither agent, as employed in this study, was able to produce an objective antitumor effect in this group of patients with previous chemotherapeutic exposure. At the dosages used in this study, neither agent can be recommended for further treatment of advanced breast cancer.
D000328:Adult; D000368:Aged; D000577:Amides; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005493:Folic Acid Antagonists; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D011720:Pyrazoles; D012263:Ribonucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012266:Ribose; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000577:Amides; D000903:Antibiotics, Antineoplastic; D005493:Folic Acid Antagonists; D011720:Pyrazoles; D012263:Ribonucleosides; D014227:Triazines; C002997:pyrazofurin; D012266:Ribose; C012071:triazinate